FGF1 and peripheral arterial disease: Despite a large number of positive preclinical and early clinical studies, the results of growth-factor based pro-angiogenic clinical trials for PAD finally were negative in a large randomized phase III study using FGF-1 gene therapy [8]–[12], [22], [23].